These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 11454674)

  • 1. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
    Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.
    Johns TG; McKay MJ; Cvrljevic AN; Gan HK; Taylor C; Xu H; Smyth FE; Scott AM
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):572-8. PubMed ID: 20638193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
    Fan Z; Baselga J; Masui H; Mendelsohn J
    Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
    Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
    Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
    Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
    Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
    Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
    Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
    Bigner SH; Humphrey PA; Wong AJ; Vogelstein B; Mark J; Friedman HS; Bigner DD
    Cancer Res; 1990 Dec; 50(24):8017-22. PubMed ID: 2253244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
    Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy.
    Hambek M; Solbach C; Schnuerch HG; Roller M; Stegmueller M; Sterner-Kock A; Kiefer J; Knecht R
    Cancer Res; 2001 Feb; 61(3):1045-9. PubMed ID: 11221831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.